William Blair assumed coverage on shares of Prevail Therapeutics (NASDAQ:PRVL) in a research report sent to investors on Monday morning, Benzinga reports. The brokerage issued an outperform rating and a $25.00 price objective on the stock. William Blair also issued estimates for Prevail Therapeutics’ Q3 2020 earnings at ($0.72) EPS, Q4 2020 earnings at ($0.78) EPS, FY2020 earnings at ($2.72) EPS, Q1 2021 earnings at ($0.80) EPS, Q2 2021 earnings at ($0.80) EPS, Q3 2021 earnings at ($0.63) EPS, Q4 2021 earnings at ($0.64) EPS, FY2021 earnings at ($2.82) EPS, FY2022 earnings at ($2.72) EPS, FY2023 earnings at ($2.87) EPS and FY2024 earnings at ($2.95) EPS.

Other research analysts have also issued research reports about the company. Wedbush lifted their price target on Prevail Therapeutics from $19.00 to $22.00 and gave the stock an outperform rating in a research report on Tuesday, May 26th. Zacks Investment Research lowered Prevail Therapeutics from a hold rating to a sell rating in a research report on Friday, August 14th. Oppenheimer reaffirmed a buy rating and set a $25.00 price target on shares of Prevail Therapeutics in a research report on Wednesday, July 29th. Stifel Nicolaus started coverage on Prevail Therapeutics in a research report on Wednesday, July 15th. They set a buy rating and a $23.00 price target on the stock. Finally, ValuEngine raised Prevail Therapeutics from a hold rating to a buy rating in a research report on Monday, August 24th. Two research analysts have rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $22.75.

Shares of NASDAQ PRVL opened at $11.87 on Monday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 9.50 and a current ratio of 9.50. Prevail Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $19.96. The firm has a market capitalization of $406.13 million, a PE ratio of -5.01 and a beta of 1.19. The stock’s 50-day simple moving average is $13.10 and its 200-day simple moving average is $14.47.

Prevail Therapeutics (NASDAQ:PRVL) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.07). On average, sell-side analysts forecast that Prevail Therapeutics will post -2.53 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of PRVL. BlackRock Inc. boosted its stake in shares of Prevail Therapeutics by 59.3% in the first quarter. BlackRock Inc. now owns 1,133,979 shares of the company’s stock valued at $13,823,000 after buying an additional 422,205 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Prevail Therapeutics by 162.0% in the first quarter. Victory Capital Management Inc. now owns 4,748 shares of the company’s stock valued at $58,000 after buying an additional 2,936 shares in the last quarter. American International Group Inc. boosted its stake in shares of Prevail Therapeutics by 78.8% in the first quarter. American International Group Inc. now owns 8,307 shares of the company’s stock valued at $101,000 after buying an additional 3,662 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Prevail Therapeutics in the first quarter valued at approximately $159,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Prevail Therapeutics by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 225,154 shares of the company’s stock valued at $2,745,000 after buying an additional 11,664 shares in the last quarter. Hedge funds and other institutional investors own 82.59% of the company’s stock.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

See Also: Bollinger Bands

Analyst Recommendations for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.